VectorY is growing PIONEER-ALS from 12 to 36 participants to test VTx-002, an antibody therapy aimed at the protein TDP-43.

BodySpec’s new storefront targets muscle loss from GLP-1 weight loss drugs, with scans said to take about 12 minutes.

A Censuswide survey commissioned by PortionIQ finds confidence is lower among longer-term users, though it’s a snapshot from one brand.

Forget the diagnosis count. The researcher who helped the WHO reframe aging says function, not disease, is the better yardstick.

A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an ...

QIMA Life Sciences launches SQINGEVITY, bringing biological testing and clinical studies together to examine claims about ...

All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is ...

Mighty Therapeutics and the University of Washington will use pilot data on elamipretide to design a larger trial in older ...

Forecast for rapid growth by 2033, with disease-modifying therapies driving sales – and healthcare systems confronting the cost of access.

Patent cliffs and falling R&D productivity push the biggest players toward other people's science – our report puts numbers ...

Monte Rosa’s NEK7-targeting drug pulled several heart-risk biomarkers toward healthy levels in 108 people with obesity.

A Lancet Neurology study of 130 blood proteins in patients receiving lecanemab suggests amyloid clearance and cognitive ...